Global Atherosclerosis Pipeline Review: H2 2019 -

DUBLIN--()--The "Atherosclerosis - Pipeline Review, H2 2019" drug pipelines has been added to's offering.

This report provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

The review provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 2, 2, 3, 6, 1, 36, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular).

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • 13therapeutics Inc
  • Abcentra LLC
  • ABIONYX Pharma SA
  • AFFiRiS AG
  • Allysta Pharmaceuticals Inc
  • Amgen Inc
  • Annexin Pharmaceuticals AB
  • AptaBio Therapeutics Inc
  • Artery Therapeutics Inc
  • Asdera
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Auxagen Inc
  • Band Therapeutics LLC
  • BBN Cardio Therapeutics
  • Boehringer Ingelheim International GmbH
  • Centeer BioTherapeutics Ltd Co
  • CohBar Inc
  • Corbus Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DoNatur GmbH
  • Esperion Therapeutics Inc
  • General Regeneratives Shanghai Ltd
  • GenKyoTex SA
  • Immusoft Corp
  • Innolife Co Ltd
  • Inotrem SA
  • Inspyr Therapeutics Inc
  • Iproteos SL
  • Jenrin Discovery Inc
  • Kaleido Biosciences Inc
  • KineMed Inc
  • Kiromic Inc
  • Kowa Co Ltd
  • LG Chem Ltd
  • LipimetiX Development Inc
  • Mperia Therapeutics Inc
  • Novartis AG
  • NuSirt Biopharma Inc
  • Omeros Corp
  • Pharmahungary Group
  • Regeneron Pharmaceuticals Inc
  • Repair Biotechnologies Inc
  • Riparian Pharmaceuticals Inc
  • Sansho Co Ltd
  • Serene LLC
  • Shin Poong Pharm Co Ltd
  • Signablok Inc
  • The Medicines Company
  • Tiara Pharmaceuticals Inc
  • Vascular Biogenics Ltd
  • VasThera Research Institute
  • Vaxil Bio Therapeutics Ltd
  • Vicore Pharma AB
  • Wooridul Pharmaceutical Ltd
  • XBiotech Inc

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900